慢病毒基因治疗X连锁慢性肉芽肿病的初步结果
在两项首次人体研究中,9例严重X连锁慢性肉芽肿病患者接受清髓预处理后,输注慢病毒转导的自体CD34+造血干/祖细胞。12个月时,7例存活者中6例载体拷贝数稳定(0.4-1.8拷贝/中性粒细胞),16-46%中性粒细胞氧化酶阳性,无克隆失调或转基因沉默,未出现新的CGD相关感染,6例停用抗生素预防。
要点
- 慢病毒基因治疗可稳定重建X-CGD患者中性粒细胞氧化酶功能。
- 6/9患者达到主要终点,存活者无新发CGD相关感染。
- 2例早期死亡与既存合并症相关,非基因治疗直接毒性。
核心结论
- 自体慢病毒基因治疗在部分X-CGD患者中可实现生化与功能重建,是 promising 的治疗策略。
研究设计与样本
- 首次人体研究(NCT02234934和NCT01855685),纳入9例严重X-CGD患者,清髓预处理后输注慢病毒转导的自体CD34+造血干/祖细胞。
- 主要目标为12个月时安全性和评估生化与功能重建的疗效及稳定性。
主要发现
- 12个月时,7例存活者中6例载体拷贝数稳定(0.4-1.8拷贝/中性粒细胞),16-46%中性粒细胞氧化酶阳性。
- 无克隆失调或转基因沉默的分子证据。
- 存活患者无新的CGD相关感染,6例停用CGD相关抗生素预防。
- 2例患者在治疗3个月内因既存合并症死亡。
关键数值与推荐
- 12个月随访时,9例患者中6例达到主要目标。
临床怎么用
- 对于严重X-CGD患者,自体慢病毒基因治疗可能提供稳定功能重建并减少感染预防需求。
局限性
- 样本量小(9例),随访仅12个月,2例早期死亡与既存合并症相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic granulomatous disease (CGD) is a rare inherited disorder of phagocytic cells1,2. We report the initial results of nine severely affected X-linked CGD (X-CGD) patients who received ex vivo autologous CD34+ hematopoietic stem and progenitor cell-based lentiviral gene therapy following myeloablative conditioning in first-in-human studies (trial registry nos. NCT02234934 and NCT01855685). The primary objectives were to assess the safety and evaluate the efficacy and stability of biochemical and functional reconstitution in the progeny of engrafted cells at 12 months. The secondary objectives included the evaluation of augmented immunity against bacterial and fungal infection, as well as assessment of hematopoietic stem cell transduction and engraftment. Two enrolled patients died within 3 months of treatment from pre-existing comorbidities. At 12 months, six of the seven surviving patients demonstrated stable vector copy numbers (0.4-1.8 copies per neutrophil) and the persistence of 16-46% oxidase-positive neutrophils. There was no molecular evidence of either clonal dysregulation or transgene silencing. Surviving patients have had no new CGD-related infections, and six have been able to discontinue CGD-related antibiotic prophylaxis. The primary objective was met in six of the nine patients at 12 months follow-up, suggesting that autologous gene therapy is a promising approach for CGD patients.
引用
- Kohn DB, Booth C, Kang EM, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med. 2020. PMID: 31988463. doi:10.1038/s41591-019-0735-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。